ReviewExpert review of clinical immunology2023
Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.
Review in Expert review of clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- The value of serum biomarkers in the management of interstitial lung disease in patients with connective tissue disease: a protocol for an observational study.Journal of thoracic disease · 2026Article
- Assessment of disease severity in systemic sclerosis-associated interstitial lung disease using a modified lung ultrasound score: correlation with pulmonary function, HRCT, and clinical scores, and evaluation of diagnostic efficacy.Clinical rheumatology · 2026Article
- Diagnostic performance of lung ultrasound for systemic sclerosis-associated interstitial lung disease: an international cross-sectional study from two tertiary care centers.Clinical rheumatology · 2026Article
- Soluble immune checkpoints reflect immune activation and treatment response in high-risk systemic sclerosis patients treated with plasma exchange.Journal of translational autoimmunity · 2026Article
- Review
- Rheumatoid arthritis associated interstitial lung disease: diagnostic accuracy of lung ultrasound compared to chest high resolution computed tomography.Frontiers in medicine · 2026Article
- Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease.Current treatment options in rheumatology · 2025Article
- Comparison of quantitative lung ultrasound scores with automated quantitative CT: to overcome the ultrasound limitations.Rheumatology (Oxford, England) · 2025Article
- Interstitial Lung Disease and Pulmonary Arterial Hypertension Screening Practices in Systemic Sclerosis: Survey Insights of Rheumatologists in the Middle East and North Africa Region.Mediterranean journal of rheumatology · 2025Article
- The potential of semi-quantitative and quantitative methods in predicting progression in rheumatoid arthritis-associated interstitial lung disease.Clinical rheumatology · 2025Observational
- Warrick score in rheumatoid-arthritis interstitial lung disease: a promising tool for assessing the extent and progression of lung involvement.Advances in rheumatology (London, England) · 2025Article
- Automated AI-based image analysis for quantification and prediction of interstitial lung disease in systemic sclerosis patients.Respiratory research · 2025Article
- B-Lines in the Assessment of Interstitial Lung Disease Associated with Scleroderma: The Role of Handheld Devices.Diagnostics (Basel, Switzerland) · 2024Article
- Systemic sclerosis interstitial lung disease: unmet needs and potential solutions.Nature reviews. Rheumatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
introductionInterstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (SSc). Risk of developing progressive ILD is highest among patients with diffuse cutaneous disease, positive anti-topoisomerase I antibody, and elevated acute phase reactants. With the FDA approval of two medications and a pipeline of novel therapeutics in trials, early recognition and intervention is critical. High-resolution computed tomography of the chest is the current gold standard test for diagnosis of ILD. Yet, it is not offered as a screening tool to all patients due to which ILD can be missed in up to a third of patients. There is a need to develop and validate more innovative screening modalities. AREAS COVERED: In this review, we provide an overview of screening and diagnosis of SSc-ILD, highlighting the recent innovations particularly the role of soluble serologic, radiomic (quantitative lung imaging, lung ultrasound), and breathomic (exhaled breath analysis) biomarkers in the early detection of SSc-ILD. EXPERT OPINION: There is remarkable progress in the development of new radiomics and serum biomarkers in diagnosing SSc-ILD. There is an urgent need for conceptualizing and testing composite ILD screening strategies that incorporate these biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.